# Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

> **NCT05511519** · PHASE2 · TERMINATED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 47 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** ATI-450
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT05511519
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-12
- **Primary completion:** 2023-12-06
- **Final completion:** 2024-01-03
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05511519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05511519, "Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05511519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*